Respiratory Function in Patients With Post-tuberculosis Lung Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03821285

Recruitment Status : Unknown

Verified January 2019 by Dina Visca, Università degli Studi dell'Insubria.
Recruitment status was: Recruiting

First Posted : January 29, 2019

Last Update Posted : January 29, 2019

Sponsor:

Collaborators:

Fondazione Salvatore Maugeri

Azienda Ospedaliero Universitaria di Sassari

Instituto Nacional de Enfermedades Respiratorias

Information provided by (Responsible Party):

Dina Visca, Università degli Studi dell'Insubria

Study Description

Brief Summary:

Pulmonary tuberculosis (TB) is an important risk factor for chronic respiratory disease due to residual lung damage. A recent review of the literature on TB sequelae and rehabilitation has provided clear evidence that TB is definitively responsible for lung function impairment. Functional evaluation of TB patients after completion of pulmonary tuberculosis treatment or spontaneous healing should be considered as part of clinical care. Unfortunately, few studies are available in the literature investigating the physiopathology of lung damage, its impact on quality of life, the potential need for pulmonary rehabilitation (PR), and the effects of a PR program.Objectives of this prospective multicentre international study are: Primary Objective-to assess the exercise capacity 6-min walking test in patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment or after spontaneous healing. Secondary Objectives-to assess the effects of the PR program on dyspnoea symptoms and muscle fatigue, quality of life.

Condition or disease	Intervention/treatment	Phase
Lung Diseases, Obstructive Pulmonary Rehabilitation Lung TB	Procedure: Pulmonary Rehabilitation	Not Applicable

Show detailed description

Detailed Description:

Methods Respiratory functional parameters at baseline and at the end of the 15 sessions rehabilitation programme (RP) will be collected at the participating Centre. Follow-up visit 1 year after completion of RP Baseline assessment

After signature of the informed consent to the study, patients will undergo a Pre-screening Visit: data on medical history, current pharmacological therapies, smoking (pack/year), vaccinations, physical examination, vital parameters (blood pressure, heart rate, respiratory rate, oxygen saturation in arterial blood), co-morbidities and Mini Mental State Examination will be collected.
Screening Visit (before the RP), during the visit the following data will be collected: number of TB disease episodes, detailed data on the last TB episode (age at onset of TB symptoms, age at TB diagnosis, anti-TB treatment duration, anti-TB drugs administered, socio-economic conditions, education level, physical examination, vital parameters, oxygen saturation in arterial blood, heart rate and respiratory rate). Pulmonary rehabilitation program tailored according to specific patient's needs.
Baseline assessment of respiratory function: arterial blood gas (ABG) analysis, spirometry, diffusing capacity of the lungs for carbon monoxide (DLCO), overnight oximetry, electrocardiogram (ECG), chest X-ray (CXR), High-resolution computed tomography (HRCT)
Assessment of the rehabilitation programme: functional evaluation (6MWT), muscle strength evaluation (five-repetition sit-to-stand test (5STS)), respiratory muscle strength (maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)), symptoms evaluation (Dyspnea: Medical Research Council Questionnaire (MRC), Modified Borg pre/post 6MWT, Baseline and Transition Dyspnea Indexes (BDI-TDI) and Fatigue: Modified Borg pre/post 6MWT)
Assessment of the Quality of Life (QoL): CAT and St George's Respiratory Questionnaire.

Final assessment:

A final assessment will be done at the end of the rehabilitation programme and will include:

c) Only ABG, spirometry and DLCO d) and e).

Pulmonary rehabilitation programme

PR programme will include:

At least 15 aerobic-training sessions by cycle ergometer supervised by a respiratory therapist (5 session per week, 30 minutes each: 5 minutes warm up, 20 minutes training and 5 minutes warm-down) at constant load (calculated with Hill equation, Hill K, et al. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008;89(9):1782-7.) with an adherence of at least 80%.

At least 15 strength-training sessions for peripheral muscles (30 minutes calisthenics exercise) with an adherence of at least 80%.
At least 3 face to face and/or group educational sessions, for:
- Optimization of inhalation techniques
- Exercise training and maintenance programs
- Daily physical activity
- Airways clearance techniques
- Long oxygen therapy home management.
According to individual needs, the PR program should include:
- airways clearance techniques
- inspiratory muscles training (with Threshold®)

Monitoring Anonymous data will be collected in a common electronic format (excel database).

Adverse events (AEs) and severe adverse events (SAEs) will be reported and registered.

Follow-up

Follow-up visit 1 year after completion of RP will include:

c) Only ABG, spirometry, DLCO and overnight oximetry d) and e) Statistical analysis A two-tailed p-value less than 0.05 will be considered statistically significant.

Qualitative and quantitative variables will be described with absolute and relative (percentages) frequencies and means (standard deviations -SD) or medians (interquartile ranges -IQR) depending on their normality, respectively. The mean difference between the two study groups in the 6MWT will be evaluated using the Student's t-test. Differences in the variables associated to the secondary objectives will be evaluated using the Chi-square or Student's t-test for qualitative and quantitative variables. A two-tailed p-value less than 0.05 will be considered statistically significant.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	100 participants
Allocation:	N/A
Intervention Model:	Single Group Assignment
Intervention Model Description:	Prospective, multicentre international
Masking:	None (Open Label)
Primary Purpose:	Screening
Official Title:	Evaluation of Respiratory Function in Patients With Post-tuberculosis Lung Impairment After Pulmonary Tuberculosis Treatment or After Spontaneous Healing
Estimated Study Start Date :	February 14, 2019
Estimated Primary Completion Date :	July 31, 2020
Estimated Study Completion Date :	January 14, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rehabilitation Tuberculosis

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: pulmonary rehabilitation Pulmonary rehabilitation program	Procedure: Pulmonary Rehabilitation Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training

Outcome Measures

Primary Outcome Measures :

6-min walking test [ Time Frame: 1 year ]
Exercise capacity

Secondary Outcome Measures :

dyspnoea [ Time Frame: 1 year ]
Modified BORG scale (0-10) 0 better, 10 worse
muscle fatigue [ Time Frame: 1 year ]
Modified Borg scale (0-10) 0 better, 10 worse
health related quality of life [ Time Frame: 1 year ]
st. George Respiratory Questionnaire 0 better, 100 worse
health status [ Time Frame: 1 year ]
COPD Assessment test-CAT (0-40) 0 better, 40 worse

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

- Patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment - Patients with post- TB impairment after spontaneous healing

Exclusion Criteria:

Any unstable medical condition
Musculoskeletal disorders contraindicating participation in the PR program
Cognitive impairment (Mini Mental State Examination <22)
Unable to sign informed consent

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03821285

Contacts

Layout table for location contacts

Contact: Dina Visca, Dr	+390331829111	dina.visca@icsmaugeri.it
Contact: Elisabetta Zampogna, Dr	+390331829503	elisabetta.zampogna@icsmaugeri.it

Locations

Layout table for location information

Italy
ICS Maugeri, IRCCS	Recruiting
Tradate, Varese, Italy, 21049
Contact: Dina Visca, Dr +390331829111 dina.visca@icsmaugeri.it
Contact: Elisabetta Zampogna, Dr +390331829503 elisabetta.zampogna@icsmaugeri.it

Sponsors and Collaborators

Università degli Studi dell'Insubria

Fondazione Salvatore Maugeri

Azienda Ospedaliero Universitaria di Sassari

Instituto Nacional de Enfermedades Respiratorias

Investigators

Layout table for investigator information

Study Director:	Giovan Battista Migliori, Prof	ICS Maugeri, IRCCS

More Information

Publications of Results:

Muñoz-Torrico M, Rendon A, Centis R, D'Ambrosio L, Fuentes Z, Torres-Duque C, Mello F, Dalcolmo M, Pérez-Padilla R, Spanevello A, Migliori GB. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? J Bras Pneumol. 2016 Sep-Oct;42(5):374-385. doi: 10.1590/S1806-37562016000000226. Review. English, Portuguese.

Other Publications:

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24. Review.

Layout table for additonal information

Responsible Party:	Dina Visca, Principal Investigator, Università degli Studi dell'Insubria
ClinicalTrials.gov Identifier:	NCT03821285
Other Study ID Numbers:	2215CE
First Posted:	January 29, 2019 Key Record Dates
Last Update Posted:	January 29, 2019
Last Verified:	January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Dina Visca, Università degli Studi dell'Insubria:


TB Pulmonary rehabilitation Lung function

Additional relevant MeSH terms:

Layout table for MeSH terms

Tuberculosis Lung Diseases Lung Diseases, Obstructive Mycobacterium Infections	Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Respiratory Tract Diseases

To Top